MONDAY, June 9 (HealthDay News) -- The medication rosiglitazone may slow the progression of eye disease in diabetes patients, according to new research from the Jules Stein Eye Institute at the University of California, Los Angeles.

Specifically, researchers found that patients who took the drug were less likely to develop proliferative diabetic retinopathy or to experience reductions in visual acuity (sharpness). But they are not recommending the drug's use until further studies are done.

By Serena Gordon
EmpowHer's HealthDay Reporter

FRIDAY, May 2 (HealthDay News) -- While diabetes has long been associated with the potentially sight-stealing disease diabetic retinopathy, it appears that another serious eye disease -- glaucoma -- may also be a complication of the metabolic disorder.

A recent study in the journal Ophthalmology found that women with diabetes have about a 70 percent increased risk of developing the most common form of glaucoma -- primary open-angle glaucoma -- compared to women without diabetes.

By Jeffrey Perkel
HealthDay Reporter

MONDAY, March 17 (HealthDay News) -- Researchers have pinpointed a biological pathway that may block the blood vessel proliferation and leakiness behind most cases of blindness in the United States.

Though still preliminary, the University of Utah study suggests a new therapeutic target for such ophthalmic diseases as age-related macular degeneration (AMD) and diabetic retinopathy, as well as other conditions marked by inflammation and vascular leakiness, including cancer and certain traumatic injuries.